Clinically validated VHH antibodies that can be readily assembled to create well differentiated next generation biotherapeutics.

Application of

LlamdA® Antibodies

LlamdA® VHH can be assembled to create bispecific and multi-specific biotherapeutics.

It can also be used to achieve targeted drug delivery as components of ADCs and cell and gene therapies including CAR-Ts.

Applications of

LlamdA® Antibodies

Benefits of

LlamdA® Antibodies

Direct Therapeutics

VHH’s small size makes them advantageous for isolating binders to intractable targets (eg membrane proteins) and buried epitopes. Half life tunable via serum albumin binding VHH.

VHH Bispecifics

VHH can be combined with IgG to create bispecifics with novel mechanisms of action and high specificity. VHH-only multispecifics offer gain of selectivity and improved tumour penetration for solid tumours

Antibody Drug Conjugates (ADC)

VHH formattable to deliver payloads (Radio- nucleotides, toxins, RNAi) with high specificity and tunable on/off rates.

VHH as targeting agent in Cell and Gene therapies

Small, stable alternative to scFv. VHH offer improved developability and manufacturability. Novel VHH can be readily formatted for incorporation into cell and gene therapies.


VHH Features

VHH Applications

Partnerships at Isogenica

Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.